Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06840496 · ClinicalTrials.gov registry record · Phase 3

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

A Phase 3 study of Rett Syndrome, sponsored by Biomed Industries.

Recruiting
Registry status
Phase 3
Development phase
210
Enrollment target
20
Study locations

NCT06840496 is a Phase 3 study of Rett Syndrome that is actively recruiting participants, run by Biomed Industries. The registered enrollment target is 210 participants, below the 514-participant average among 18 other Rett Syndrome trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06840496, a Phase 3 study of Rett Syndrome, is actively recruiting participants, sponsored by Biomed Industries.

RECRUITING
Registry status
Phase 3
Development phase
210 participants
Enrollment target
20
Study locations

Study Summary

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome

Conditions Studied

Rett Syndrome

Interventions

  • DRUG Placebo
  • DRUG Bionetide

Study Locations (20)

California

  • Biomed Testing Facility # BIO-05-92093 - La Jolla
  • Biomed Testing Facility # BIO-04-90095 - Los Angeles
  • Biomed Testing Facility # BIO-03-95817 - Sacramento
  • Biomed Testing Facility # BIO-02-94104 - San Francisco

Ohio

  • Biomed Testing Facility #BIO-15-45229 - Cincinnati
  • Biomed Testing Facility #BIO-16-44195 - Cleveland

Arizona

  • Biomed Testing Facility # BIO-01-85012 - Phoenix

Colorado

  • Biomed Testing Facility #BIO-06-80042 - Aurora

Florida

  • Biomed Testing Facility #BIO-07-33606 - Tampa

Illinois

  • Biomed Testing Facility #BIO-08-60612 - Chicago

Maryland

  • Maryland Locations Biomed Testing Facility #BIO-9-21205 - Baltimore

Massachusetts

  • Biomed Testing Facility #BIO-10-02115 - Boston

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2025-10-30
Est. Completion 2026-11-30
Phase Phase 3

Sponsor

Biomed Industries

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06840496

The ClinicalTrials.gov registry entry for NCT06840496 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 514-participant average among 18 other Rett Syndrome trials with a reported enrollment target (59% lower). The listed sponsor is Biomed Industries, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rett Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06840496 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Ohio, Arizona.

Frequently Asked Questions

What is clinical trial NCT06840496 about?

NCT06840496 is a clinical study titled "To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome". Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrom...

What is the current status of trial NCT06840496?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2025-10-30. Estimated completion is 2026-11-30.

What conditions does trial NCT06840496 study?

This clinical trial studies the following conditions: Rett Syndrome.

What interventions are being tested in trial NCT06840496?

The interventions under investigation include: Placebo (DRUG), Bionetide (DRUG).

Who is sponsoring clinical trial NCT06840496?

This trial is sponsored by Biomed Industries, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06840496 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rett Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rett Syndrome

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.